Long-term treatment of rheumatoid arthritis with tumour necrosis factor α blockade:: outcome of ceasing and restarting biologicals

被引：29

作者：

Buch, MH ^{[1
]}

Marzo-Ortega, H ^{[1
]}

Bingham, SJ ^{[1
]}

Emery, P ^{[1
]}

机构：

[1] Univ Leeds, Acad Unit Musculoskeletal Dis, Gen Infirm, Leeds LS1 3EX, W Yorkshire, England

来源：

RHEUMATOLOGY | 2004年 / 43卷 / 02期

关键词：

D O I：

10.1093/rheumatology/keg454

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：243 / 244

页数：2

共 3 条

[1] Infliximab and methotrexate in the treatment of rheumatoid arthritis [J].

Lipsky, PE ;

van der Heijde, DMFM ;

St Clair, EW ;

Furst, DE ;

Breedveld, FC ;

Kalden, JR ;

Smolen, JS ;

Weisman, M ;

Emery, P ;

Feldmann, M ;

Harriman, GR ;

Maini, RN .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1594-1602

[2] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].

Maini, R ;

St Clair, EW ;

Breedveld, F ;

Furst, D ;

Kalden, J ;

Weisman, M ;

Smolen, J ;

Emery, P ;

Harriman, G ;

Feldmann, M ;

Lipsky, P .

LANCET, 1999, 354 (9194) :1932-1939

[3]

*NAT I CLIN EXC, 2002, TECHN APPR GUID, V36

← 1 →